Evaluating Minimal Important Differences for the FACT-Melanoma Quality of Life Questionnaire  by Askew, Robert L. et al.
Evaluating Minimal Important Differences for the
FACT-Melanoma Quality of Life Questionnairevhe_570 1144..1150
Robert L. Askew, BA,1 Yan Xing, MD, PhD, MS,1 J. Lynn Palmer, PhD,2 David Cella, PhD,3
Lemuel A. Moye, MD, PhD,4 Janice N. Cormier, MD, MPH1
1Department of Surgical Oncology,The University of Texas M.D.Anderson Cancer Center, Houston,TX, USA; 2Department of Palliative Care
and Rehabilitation Medicine,The University of Texas M.D.Anderson Cancer Center, Houston,TX, USA; 3Center on Outcomes, Research, and
Education, Evanston Northwestern Healthcare, Evanston, IL, USA; 4Department of Biostatistics,The University of Texas School of Public
Health, Houston,TX, USA
ABSTRACT
Objectives: Minimal Important Differences (MIDs) establish benchmarks
for interpreting mean differences in clinical trials involving quality of life
outcomes and inform discussions of clinically meaningful change in
patient status. The purpose of this study was to assess MIDs for the
Functional Assessment of Cancer Therapy-Melanoma (FACT-M).
Methods: A prospective validation study of the FACT-M was performed
with 273 patients with stages I through IV melanoma. FACT-M, Karnof-
sky Performance Scales, and Eastern Cooperative Oncology Group Per-
formance Status scores were obtained at baseline and 3 months following
enrollment. Anchor- and distribution-based methods for assessing MIDs
were compared, and pattern-mixture modeling was employed to derive
multivariate adjusted estimates.
Results: This study indicates that an approximate range for MIDs of the
FACT-M subscales is between 5 to 9 points for the Trial Outcome Index,
4 to 6 points for the Melanoma Combined Subscale, 2 to 4 points for the
Melanoma Subscale, and 1 to 2 points for the Melanoma Surgery Sub-
scale. Each method produced similar but not identical ranges of MIDs.
Conclusions: The properties of the anchor instrument employed to derive
MIDs directly affect resulting MID ranges and point values. When MIDs
are offered as supportive evidence of a clinically meaningful change, the
anchor instrument used to derive clinically meaningful thresholds of
change should be clearly stated along with information supporting the
choice of anchor instrument as the most appropriate for the domain of
interest.
Keywords: Functional Assessment of Cancer Therapy, melanoma,
minimal important differences, patient reported outcomes, quality of life.
Introduction
Quality of life (QOL) measures in cancer research have been
shown to be independent predictors of both survival and
response to therapy [1–5], and for melanoma in particular, QOL
has been shown to be an independent predictor of survival for
patients with advanced disease [2,6]. Patient reported outcomes
such as QOL can serve multiple purposes, including acting as
validation measures of treatment efﬁcacy in the context of clini-
cal trials and serving as reference points for clinical decision-
making when modest differences in survival are anticipated
among various treatment modalities [7–9].
With respect to measuring and reporting patient reported
outcomes in the context of clinical trials, the US Food and Drug
Administration published 2006 draft guidance on the methods to
derive and interpret Minimal Important Differences (MIDs) for
QOL instruments [7]. In this document, which was primarily
intended to serve as a guidance for industry related to product/
drug labeling, MIDs are deﬁned as the minimum change
observed in a patient reported outcome measure (e.g., QOL
score) between treatment groups that can be correlated with or
interpreted as a treatment beneﬁt. With the increasingly acknowl-
edged importance of patient reported outcomes in the context of
clinical trials [7,10], the assessment of MIDs for QOL instru-
ments is central to interpreting study results, in that they can
both establish benchmarks for interpreting mean differences and
inform the discussion of what constitutes a clinically meaningful
change. A variety of techniques have been employed to determine
MIDs [7], including distribution-based methods [11–13], anchor-
based methods [14,15], empirical rules [16], or combinations of
methods [17–23]. These techniques have been applied to many
cancer-related QOL instruments, including the Functional
Assessment of Cancer Therapy (FACT)-Lung, FACT-Prostate,
FACT-Colorectal, and the FACT-Breast [17–22,24], but to date,
there has been no comprehensive assessment of MIDs for the
FACT-Melanoma (FACT-M) QOL questionnaire.
The Functional Assessment of Chronic Illness and Therapy is
a patient reported outcome measurement system composed of a
general health-related QOL component for patients with chronic
disease coupled with disease-speciﬁc modules [25,26]. This
hybrid approach for measuring patient reported outcomes has
the advantage of allowing for both a more focused assessment of
disease-speciﬁc proﬁles and symptoms while retaining compara-
bility across populations due to the common core items [27]. For
example, for patients undergoing treatment for cancer, the FACT-
General (FACT-G) serves as the general component, and for
those with speciﬁc malignancies such as melanoma, the general
items of the FACT-G are supplemented with the melanoma-
speciﬁc items of the FACT-M. The FACT-M was developed at the
University of Texas M.D. Anderson Cancer Center and has been
validated as a patient-reported QOL measure for melanoma
patients with American Joint Committee on Cancer stages I
through IV disease [28,29].
The objectives of this study were to derive MIDs for the
FACT-M using anchor-based methods, to conduct a comparative
distribution-based analysis, and to assess the correspondence
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among MID ranges derived from each of the employed
methods.
Methods
Clinical, demographic, and QOL data were collected prospec-
tively at the Melanoma and Skin Center of the University of
Texas M.D. Anderson Cancer Center in Houston, Texas with the
approval of the institutional review board for the protection of
human subjects. From 2004 to 2005, new patients and those
within 3 years of melanoma diagnosis were recruited when they
presented for scheduled appointments, with recruitment efforts
targeting an equal proportion of patients with local, regional,
and distant metastatic disease. With 80 patients per disease stage
grouping (I and II, III, IV), a statistically signiﬁcant difference in
effect sizes of 0.45 or greater could be detected with 80% statis-
tical power. Initial sampling targets were set at 300 participants
to account for attrition, while assuring sufﬁcient sample size at
analysis. Study participants had to be at least 18 years of age and
ﬂuent in English, and enrollment required pathological conﬁr-
mation of melanoma. Exclusion criteria included inability to
consent due to other medical illnesses and disorientation to
person, place, or time. Written informed consent was obtained
for each of the study participants, and questionnaires were com-
pleted at baseline and during regularly scheduled follow-up
visits. Clinical data were abstracted from patient ﬁles at baseline
and for respective follow-up time points.
Instruments
The FACT-M is composed of items from the FACT-G,
melanoma-speciﬁc items, and items related to melanoma surgery
[28,29]. Four constructs comprise the FACT-G scale, with seven
items assessing Physical Well-Being (PWB), seven items assessing
Social/Family Well-Being, six items assessing Emotional Well-
Being, and seven items assessing Functional Well-Being (FWB).
With the addition of the 16-item Melanoma Subscale (MS) and
the 8-item Melanoma Surgery Subcale (MSS)—collectively
known as the Melanoma Combined Scale (MCS), the number of
items of the FACT-M totals 51. Each of these subscales has been
shown to have high levels of internal consistency (Cronbach’s a:
0.71–0.95) and high test–retest reliability (r: 0.71–0.90) [29].
Higher scores on any subscale or total score indicate higher levels
of QOL [26]. The Trial Outcome Index (TOI), which is often the
most appropriate single patient-reported end point in clinical
trials [22], has been deﬁned as the summed score of the seven
PWB and seven FWB items from the FACT-G and the disease-
speciﬁc subscale items.
The Karnofsky Performance Scale (KPS) is designed to assess
a patient’s status in terms of functional impairment. With a range
of 0 (dead) to 100 (normal—no evidence of disease), this scale
assists clinicians and caretakers in gauging a patient’s ability to
perform activities basic to daily living [30,31]. The KPS was
administered at the time of study entry and 3 months later. The
Eastern Cooperative Oncology Group Performance Status
(ECOG-PS) scale is a measure of disease progression and its effect
on a patient’s daily living [32,33]. The range of the scale is from
0 (representing fully active, pre-disease performance status) to 5
(death). Clinicians assessed patient performance status at base-
line and at 3 months to correspond in timing with the other
assessments.
Statistical Analysis
Baseline demographic and clinical data were summarized, and
FACT-M TOI, MCS, MS, and MSS scores were calculated
using STATA statistical software (v. SE9.2, StataCorp, College
Station, TX, USA). Mean FACT-M scores were compared
across groups based on relevant clinical indicators previously
assessed for statistically signiﬁcant score differences (e.g.,
disease stage and treatment status) [29]. Patient performance
status was assessed at the time of study entry (baseline) and
again after 3 months. For the KPS, an increase or decrease of
10 or more units on a 100-unit scale over time was considered
clinically meaningful. The ECOG-PS scale is inverted, and an
increase or a drop of one or more units on the six-unit scale
was considered clinically meaningful. Patient groups (improv-
ing, remaining stable, and declining) were created based on
these respective performance measures, and mean per-patient
change in QOL scores were calculated for each of these groups.
The differences between the QOL change scores of the various
patient performance groups were identiﬁed and served as
minimal units of clinically meaningful change in patient QOL
[22].
To facilitate a patient-visit level analysis and to mitigate the
effect of missingness that is common to studies involving QOL
outcomes, a pattern mixture model analysis was employed fol-
lowing previously established methods [23,34,35]. Using SAS
version 9.1 (SAS Institute, Cary, NC, USA) for Windows, sepa-
rate analyses were conducted with the clinical anchors serving as
independent variables, the FACT-M subscales serving as depen-
dant variables, and several clinical variables with group-level
differences in QOL such as disease stage, treatment status, and
drop out status serving as covariates in the model.
Several distribution-based methods were also included for
comparison, though the authors recognize that distribution-
based methods provide no direct information about differences
that are minimal and important [36,37]. From the methods of
Wyrwich et al, the standard error of measurement (SEM) method
was used to approximate minimum relevant thresholds of
change, as the SEM has been shown to align with MID estimates
for other important QOL instruments [13]. The SEM method
employs the formula
SEM relx xx= −( )σ 1 1 2 (1)
where sx is the standard deviation of the sample and relxx is an
appropriate measure of reliability for the instrument—in this
case, Cronbach’s alpha. Separate SEMs were calculated for
each time point (baseline and 3 months) and served as com-
parative reference points for the MID. Measures of effect size
have also served as distribution-based reference points for
MIDs [38–40]; however, effect sizes are distributionally stan-
dardized and thus not in the form of a scale score. Based on the
correspondence of modiﬁed standard deviation measures (1/3
SD and 1/2 SD) to small and moderate effect sizes, respectively
[38], the standard deviation measures of the FACT-M scale
scores were divided by two and separately by three to reﬂect
standards of change in the form of scale scores. This step was
repeated for each measurement time point (i.e., baseline and 3
months), and again for the standard deviation of per-patient
change.
As missing data is a common issue for studies assessing QOL
[41], it was important to examine how missingness may have
affected the MID estimates. Baseline demographic and clinical
characteristics of study participants who completed 3 months of
follow-up were compared to those for whom no follow-up data
were available. Subsequent analyses included tests of association
between missingness and each of the demographic and clinical
variables, while the inﬂuence of potential covariates was
examined.
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Results
A total of 273 patients were enrolled in the prospective study,
and 163 completed assessments at 3 months. Relatively even
patient distributions were observed across levels of primary
tumor site and education (Table 1). More than 25% of patients
were undergoing active treatment at the time of study enrollment
with the remainder in post-treatment follow-up surveillance.
Stratifying change in QOL by baseline clinical characteristics
uncovered signiﬁcant group differences in QOL scale scores
between patients with local-regional and advanced disease
(P < 0.001) and between those in active treatment or in
follow-up surveillance (P < 0.001). Differences in TOI scale
scores ranged from 12 to 14 points, and for the MCS, they
ranged from 6 to 7 points. For the MS and the MSS, differences
ranged from 4 to 5 points and 1 to 3 points, respectively. These
point differences were expected to provide theoretical upper
limits to the MID estimates, as these patient groups were derived
from clinically observed distinctions among patients and their
corresponding treatment and QOL outcomes.
Table 2 outlines patient QOL as measured by mean FACT-M
subscale scores. The mean TOI increased from baseline (130.8)
to 3 months (136.9), and on the patient level, the mean per-
patient change in TOI score was 5.6. Similar trends were seen for
the subscales. As QOL scores improved over time, patient-
reported performance status improved, as reﬂected in both the
KPS and ECOG-PS scores. With increasing scores reﬂecting
improvement in patient performance status, the baseline mean
KPS score of 93.0 at baseline rose to 95.4 at 3 months with a
mean per-patient change of 1.7. Similarly, performance status
improved over time on the ECOG-PS with decreasing scale scores
representing better health states. The mean ECOG-PS scale score
at baseline was 0.3 and at 3 months was 0.2 with a mean
per-patient change of -0.1 points.
Table 3 summarizes mean per-patient change in FACT-M sub-
scale scores stratiﬁed by the anchor-based performance-change
groups. Speciﬁcally, changes in QOL scores for patients whose
performance status improved were compared with scores for
patients whose performance scores decreased and with patients
whose performance status remained stable. Differences in QOL
change scores between the KPS performance groups ranged from
1.4 to 1.8 for the MSS, 1.9 to 3.4 for the MS, 3.7 to 4.8 for the
MCS, and 5.1 to 7.1 for the TOI. Similarly, for the ECOG-PS
performance groups, differences in QOL change scores ranged
from 0.9 to 2.3 for the MSS, 2.6 to 4.6 for the MS, 4.9 to 5.5 for
the MCS, and 8.3 points for the TOI.
Pattern mixture model analysis resulted in statistically signiﬁ-
cant MID estimates for each of the QOL subscales while con-
trolling for the effect of covariates (Table 4). With the KPS
serving as predictor, MID point estimates for the TOI, MCS, MS,
and MSS were 9.0, 7.1, 4.6, and 2.6, respectively. When the
ECOG-PS served as the predictor, MID point estimates were
12.2, 9.6, 6.1, and 3.5 for the respective subscales.
MID reference points from the standard deviation methods
were similar with ranges of 1.3 to 3.0 for the MSS, 1.7 to 3.8 for
the MS, 2.5 to 5.9 for the MCS, and 4.1 to 9.7 for the TOI
(Table 5). Likewise, the SEM method yielded ranges of 1.5 to 2.3
for the MSS, 2.0 to 2.9 for the MS, 2.6 to 4.1 for the MCS, and
4.1 to 6.5 for the TOI. Figure 1 illustrates the ranges of MIDs for
each of the FACT-M subscales stratiﬁed by method of analysis.
Pattern mixture model estimation resulted in higher MID ranges
than the other methods with the conﬁdence interval acting as the
Table 1 Demographic and clinical proﬁle
n = 273 %
Median age in years (range) 52 (20–79)
Race/ethnicity
White, non-Hispanic 268 98.1
Hispanic 3 1.1
African-American 1 0.4
Other 1 0.4
Gender
Male 159 58.2
Female 114 41.8
Marital status
Married 218 79.8
Never married 27 9.9
Separated or divorced 21 7.7
Widowed 7 2.6
Education
<High school 40 14.6
Some college 84 30.8
College graduate 92 33.7
Graduate school 53 19.4
Missing/Unknown 4 1.5
Primary tumor site
Head/Neck 41 15.0
Trunk/Back 69 25.3
Upper extremity 54 19.8
Lower extremity 79 28.9
Unknown primary 30 11.0
AJCC disease stage
Stages I and II 102 37.4
Stage III 100 36.6
Stage IV 71 26.0
Treatment status
Active treatment 75 27.5
Follow-up surveillance 198 72.5
Surgical procedures
Complete node dissection 133 48.7
Wide local excision and sentinel node biopsy 105 38.5
Wide local excision only 31 11.4
Fine needle aspiration 4 1.5
AJCC,American Joint Committee on Cancer.
Table 2 Mean baseline, 3 months, and per-patient change in performance and quality of life scores
Baseline 3 months Per-patient difference
n = 273 n = 163 n = 163
Mean (SD) Mean (SD) Mean (SD)
Quality of Life measures
Trial Outcome Index (PWB + FWB +MS +MSS) 130.8 (19.5) 136.9 (16.4) 5.6 (12.3)
Melanoma Combined Subscale (MS +MSS) 82.9 (11.7) 86.7 (9.2) 3.7 (7.3)
Melanoma Subscale (MS) 56.1 (7.6) 58.3 (6.1) 2.0 (5.2)
Melanoma Surgery Subscale (MSS) 26.9 (5.9) 28.4 (4.8) 1.7 (3.8)
Performance measures
Karnofsky Performance Scale 93.0 (9.0) 95.4 (8.0) 1.7 (6.8)
Eastern Cooperative Oncology Group Performance Status 0.3 (0.5) 0.2 (0.5) -0.1 (0.4)
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upper and lower bounds of the suggested MID range. Average
MID estimates from the anchor-based methods were higher than
those from the distribution-based methods, and on nearly every
scale, the MIDs from the ECOG-PS were higher than those from
the KPS.
Because a nearly 40% attrition rate for this study was
observed at 3 months, group comparisons between patients with
and without follow-up data were made for all baseline demo-
graphic and clinical characteristics. Although no statistically
signiﬁcant group differences emerged from comparisons of treat-
ment status, a signiﬁcant difference was found for baseline
disease stage (P < 0.001), with a larger proportion of patients
with metastatic disease (regional and distant) among the missing
(71.8%) than among those with follow-up data at 3 months
(56.4%). Furthermore, those with metastatic disease at baseline
were nearly twice as likely to have missing data at 3 months
(OR 1.97; 95% CI [1.17–3.30], P = 0.01), suggesting a sta-
tistical association. Subsequent examination of the relationship
between disease stage and QOL scores revealed that baseline
QOL scores differed for those with and without metastatic
disease (P < 0.001). However, when controlling for disease
stage, no association was observed between baseline QOL and
missingness.
Discussion
A comprehensive assessment of MIDs makes use of multiple
approaches to triangulate on a range of MID estimates [37], and
Table 3 Mean per-patient change in FACT-M scale scores stratiﬁed by performance-change groups
Change in
FACT-M TOI
Change in Melanoma
Combined Subscale
Change in
Melanoma Subscale
Change in Melanoma
Surgery Subscale
Mean SD Diff Mean SD Diff Mean SD Diff Mean SD Diff
Change in Karofsky Performance Status at 3 months
Improved (n = 40) 11.4 14.8 7.6 8.4 4.7 6.3 2.9 4.3
Stable (n = 110) 4.3 10.3 2.8 6.2 1.3 4.1 1.5 3.5
Declined (n = 13) -0.9 14.1 -0.9 8.5 -0.6 6.6 -0.3 4.4
Differences
(Improved ↔ Stable) 7.1 4.8 3.4 1.4
(Stable ↔ Declined) 5.1 3.7 1.9 1.8
Change in ECOG Performance Status at 3 months
Improved (n = 22) 13.1 16.6 8.1 10.2 4.4 6.6 3.7 5.8
Stable (n = 135) 4.8 10.6 3.2 6.4 1.8 4.6 1.4 3.3
Declined (n = 6) -3.5 19.2 -2.3 8.5 -2.8 7.2 0.5 3.6
Differences
(Improved ↔ Stable) 8.3 4.9 2.6 2.3
(Stable ↔ Declined) 8.3 5.5 4.6 0.9
Diff, difference; ECOG, Eastern Cooperative Oncology Group; FACT-M, Functional Assessment of Cancer Therapy-Melanoma;TOI,Trial Outcome Index.
Table 4 Pattern mixture model estimates* stratiﬁed by performance-
anchors
Estimate 95% CI P value
Karnofsky Performance Scale
Trial Outcome Index 8.95 (7.67–10.24) <0.001
Melanoma Combined Scale 7.12 (6.14–8.11) <0.001
Melanoma Subscale 4.61 (3.94–5.28) <0.001
Melanoma Surgery Subscale 2.58 (2.04–3.13) <0.001
Eastern Cooperative Oncology
Group-Performance Scale
(ECOG-PS)†
Trial Outcome Index 12.17 (9.99–14.36) <0.001
Melanoma Combined Scale 9.59 (7.90–11.27) <0.001
Melanoma Subscale 6.11 (4.97–7.26) <0.001
Melanoma Surgery Subscale 3.52 (2.62–4.42) <0.001
*Model accounts for effects of disease stage, treatment status, surgery, patient drop-out, and
interactions.
†ECOG-PS scale is inverted, but absolute values are reported in the table for consistency.
Table 5 Distribution-based ranges for minimal important differences
Standard deviation (SD) method SD baseline SD 3 months SD per-patient change
FACT-Melanoma Trial Outcome Index (TOI) 19.46 16.41 12.31
Medium effect size (TOI/2) 9.73 8.21 6.16
Small effect size (TOI/3) 6.49 5.47 4.10
Melanoma Combined Subscale (MCS) 11.73 9.22 7.35
Medium effect size (MCS/2) 5.86 4.61 3.67
Small effect size (MCS/3) 3.91 3.07 2.45
Melanoma Subscale (MS) 7.60 6.11 5.16
Medium effect size (MS/2) 3.80 3.06 2.58
Small effect size (MS/3) 2.53 2.04 1.72
Melanoma Surgery Subscale (MSS) 5.91 4.79 3.84
Medium effect size (MSS/2) 2.95 2.39 1.92
Small effect size (MSS/3) 1.97 1.60 1.28
Standard error of measurement (SEM) method SEM baseline SEM 3 months SEM per-patient change
FACT-Melanoma Trial Outcome Index 6.45 5.44 4.08
Melanoma Combined Subscale 4.06 3.19 2.55
Melanoma Subscale 2.94 2.37 2.00
Melanoma Surgery Subscale 2.29 1.86 1.49
FACT, Functional Assessment of Cancer Therapy.
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the results of this study indicate that ranges for MIDs of the
FACT-M scales are between 5 and 9 points for the TOI, 4 and 6
points for the MCS, 2 and 4 points for the MS, and 1 and 2
points for the MSS. These estimates are similar in range to those
of other cancer-speciﬁc FACT subscales [18,21,22,42]. Although
the anchor- and distribution-based methods employed to assess
MIDs resulted in similar ranges, it is important to note that they
were not the same, so the strengths and weaknesses of each
method warrant further discussion.
One strength of the distribution-basedmethods is that they can
be derived from a single sampling time point (e.g., cross-sectional
study design), and the analysis requires few statistical elements to
derive the ranges (e.g., the standard deviation of the sample and a
measure of the instrument’s reliability). However, distribution-
based methods lack clinical reference points, and because of this,
a range of MIDs derived from distribution-based methods
employed in isolation are likely to be viewed with skepticism in
regards to their clinical meaning. In contrast, anchor-based
methods for derivingMIDs make use of external reference points,
and it is from these anchors that the MID ranges derive their
clinical meaning. However, anchor-based methods generally
require assessments of change in patient health status, and mea-
sures of change require multiple assessments of a study group over
time along with the administration of multiple instruments.
Pattern mixture modeling is an anchor-based method that
minimizes the effect of missingness by accounting for it in the
model. Additionally, it allows visit-level analysis resulting in
increased statistical power when multiple visits are present in the
dataset. However, on several of the scales in this analysis, mixed
model estimates were higher than group estimates derived from
clinical distinctions that served as upper-bounds for the MIDs
(i.e., treatment status, and disease stage). Our ﬁndings that
patients with advanced disease were more likely to have missing
data at 3 months and that they were the group expected to
experience larger changes in QOL over time were not surprising.
Because mixed modeling methods incorporate all visits and cova-
riates, it is logical that MID estimates from mixed modeling were
higher than those of the other anchor-based methods. Because
the study objective was to ascertain the thresholds of minimal
difference that are clinically meaningful, when mixed model esti-
mates were above the upper thresholds set by clinical group
distinctions, the estimates derived from mixed models were given
less weight when triangulating the ﬁnal suggested range for each
subscale. There is still potential for bias from the lack of
follow-up data for patients with rapidly progressing disease [41];
however, larger differences in change scores would likely result
in larger MIDs, not smaller ones. Furthermore, the apparent
association between baseline QOL and missingness was not
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Figure 1 Ranges of Minimal Important Differences (MID) for FACT-Melanoma subscales stratiﬁed by method of analysis ( , MID range from KPS mixed model;
,MID range from ECOG-PS mixed model; ,MID range from KPS group mean; ,MID range from ECOG-PS group mean; ,MID range from Medium
Effect Size (SD/2); , MID range from Small Effect Size (SD/3); , MID range from standard error of measurement [SEM]). ECOG-PS, Eastern Cooperative
Oncology Group Performance Status; KPS, Karnofsky Performance Scale.
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signiﬁcant when controlling for covariates, and as such, further
adjustment of the MID ranges to account for missingness may
not be warranted.
At issue is what the MID ranges derived from each method
actually represent. One previously noted distinction between the
distribution- and anchor-based methods for deriving MIDs is
that they reﬂect separate underlying types of differences—the
former reﬂecting a minimal statistically quantiﬁable difference in
scores and the later reﬂecting a minimal clinically meaningful
difference in scores [43]. With this distinction in mind, comments
by de Vet et al. underscore the importance of maintaining an
integrated approach, in that by demonstrating that the clinically
meaningful differences (e.g., anchor-based MIDs) are above
the thresholds set by minimum detectable differences (e.g.,
distribution-based MIDs), the choice of the anchor instrument is
supported [43], as was found in this study. However, minor
discordance was observed among the MID ranges derived from
the anchor instruments, which warranted further examination of
the properties of each anchor instrument.
Although both the KPS and the ECOG-PS scale scores have
been strongly correlated with patient survival [44], there remains
an important distinction in their general mode of administration,
as the ECOG-PS is typically a physician-assessed measure, while
the KPS is often patient-assessed. Although others have suggested
that the ECOG-PS is a viable substitute for the KPS given its
demonstrated validity and reliability [45], the ﬁndings of this
study illustrate that substitution yields different point ranges for
MIDs. In the FACT-M validation study [29], FACT-M scores
were found to be more sensitive to change in performance status
when performance status was assessed by the KPS. The observed
increase in sensitivity with the KPS may be in-part due to issues
of instrument granularity as the KPS operates on a scale of 0 to
100 while the ECOG-PS operates on scale of 0 to 5. However,
differences in granularity are unlikely to account for all of the
observed differences in MID estimates, as interrater variability
generally increases with the increasing number of score incre-
ments available to raters [45]. Given that the acknowledged
limitations of this study include a relatively small sample size,
missingness of data, and positively skewed patient status mea-
sures, it is possible that the MIDs would realign with a larger
population of patients.
Evidence that patients provide valuable and reliable evalua-
tions of their own performance status and QOL that is better
correlated than that of their clinicians [45–47] supports the view
that MID estimates may be more appropriately derived from
patient-assessed anchor instruments—particularly when using
QOL instruments like the FACT-M that are also patient-assessed.
This point is particularly relevant to the clinical trial setting, as
the deﬁnition of a responder depends on more than just statistical
precision [7]: it depends upon the validity of the reference instru-
ments imparting clinical meaning to the observed mean differ-
ences. Our ﬁndings that the properties of the anchor instrument
directly affect the resulting MIDs support the view that when
MIDs are cited, the source anchor instrument should be included
as part of the evaluation process.
Source of ﬁnancial support: National Cancer Institute, Clinical Oncology
Research Development Program, 5-K12-CA088084.
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